adenosine monophosphate has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cornelius, V; Cro, S; Phillips, R | 1 |
| Camara, A; Cannon, J; Chandran, A; Dutta, S; Koller, A; Mattoo, S; Montenegro, P; Rochet, JC; Sanyal, A; Sengupta, R; Watson, BG; Ysselstein, D | 1 |
2 other study(ies) available for adenosine monophosphate and Parkinson Disease
| Article | Year |
|---|---|
Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials.
Topics: Adenosine Monophosphate; Alanine; Antiparkinson Agents; Antiviral Agents; Computer Graphics; COVID-19 Drug Treatment; Data Accuracy; Data Analysis; Data Display; Data Visualization; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Glial Cell Line-Derived Neurotrophic Factor; Humans; Parkinson Disease; Randomized Controlled Trials as Topic; Research Design | 2020 |
Alpha-Synuclein Is a Target of Fic-Mediated Adenylylation/AMPylation: Possible Implications for Parkinson's Disease.
Topics: Adenosine Monophosphate; alpha-Synuclein; Animals; Cell Line; Chemokine CCL7; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; HEK293 Cells; Humans; Mice; Parkinson Disease; Protein Processing, Post-Translational; Rats; Unfolded Protein Response | 2019 |